Compare Stocks

→ Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCT BriaCell Therapeutics	C$10.60 -3.8%	C$10.60	C$3.50 ▼ C$15.75	C$168.68M	N/A	12,671 shs	3,402 shs
HEB Hemispherx BioPharma	$0.43 +2.4%	$0.00	$1.69 ▼ $14.81	$1.04M	N/A	102,599 shs	255,647 shs
MTFB MOTIF BIO PLC/S	$0.11	$0.10	$0.08 ▼ $11.50	N/A	N/A	N/A	867,698 shs
NSCI Nanalysis Scientific	C$0.45 +7.1%	C$0.43	C$0.35 ▼ C$0.66	C$50.64M	0.82	65,381 shs	261,352 shs
RVV Revive Therapeutics	C$0.08 +14.3%	C$0.08	C$0.07 ▼ C$0.25	C$5.79M	N/A	93,085 shs	212,852 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCT BriaCell Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
MTFB MOTIF BIO PLC/S	0.00%	0.00%	0.00%	0.00%	0.00%
NSCI Nanalysis Scientific	+7.14%	+26.76%	+13.92%	+13.92%	-30.77%
RVV Revive Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (Ad)

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCT BriaCell Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NSCI Nanalysis Scientific	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCT BriaCell Therapeutics	N/A	N/A	N/A	N/A
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A
NSCI Nanalysis Scientific	N/A	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCT BriaCell Therapeutics	N/A	N/A	C$3.34 per share	3.17	C$3.60 per share	N/A
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A	N/A
NSCI Nanalysis Scientific	C$25.87M	1.96	C$0.05 per share	8.93	C$0.25 per share	1.80
RVV Revive Therapeutics	N/A	N/A	C$0.03 per share	3.18	C$0.02 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCT BriaCell Therapeutics	N/A	-C$0.38	N/A	∞	N/A	N/A	N/A	N/A	N/A
HEB Hemispherx BioPharma	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NSCI Nanalysis Scientific	-C$16.96M	-C$0.17	N/A	∞	N/A	-65.57%	-47.87%	-15.68%	4/25/2024 (Estimated)
RVV Revive Therapeutics	N/A	-C$0.02	N/A	∞	N/A	N/A	N/A	N/A	6/4/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCT BriaCell Therapeutics	N/A	N/A	N/A	N/A	N/A
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A
NSCI Nanalysis Scientific	N/A	N/A	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCT BriaCell Therapeutics	0.05	129.63	128.68
HEB Hemispherx BioPharma	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A
NSCI Nanalysis Scientific	71.36	1.52	1.11
RVV Revive Therapeutics	N/A	6.14	6.03

Ownership

Institutional Ownership

Company	Institutional Ownership
BCT BriaCell Therapeutics	N/A
HEB Hemispherx BioPharma	N/A
MTFB MOTIF BIO PLC/S	N/A
NSCI Nanalysis Scientific	0.03%
RVV Revive Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BCT BriaCell Therapeutics	N/A
HEB Hemispherx BioPharma	N/A
MTFB MOTIF BIO PLC/S	N/A
NSCI Nanalysis Scientific	7.11%
RVV Revive Therapeutics	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BCT BriaCell Therapeutics	5	15.91 million	N/A	Not Optionable
HEB Hemispherx BioPharma	31	2.44 million	N/A	Not Optionable
MTFB MOTIF BIO PLC/S	7	N/A	N/A	Not Optionable
NSCI Nanalysis Scientific	249	112.54 million	N/A	Not Optionable
RVV Revive Therapeutics	N/A	72.41 million	N/A	Not Optionable

NSCI, HEB, BCT, RVV, and MTFB Headlines

Source	Headline
	Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID tmcnet.com - April 23 at 8:07 AM
	Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product markets.businessinsider.com - April 18 at 8:03 AM
	Revive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID finanznachrichten.de - March 27 at 4:23 PM
	Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID finance.yahoo.com - March 27 at 10:10 AM
	Revive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID finanznachrichten.de - March 19 at 11:42 AM
	Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID markets.businessinsider.com - March 19 at 11:42 AM
	Revive Therapeutics Ltd.: Revive Therapeutics Provides Corporate Update finanznachrichten.de - March 12 at 8:23 AM
	Revive Therapeutics Provides Corporate Update financialpost.com - March 12 at 7:08 AM
	Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110 markets.businessinsider.com - February 26 at 8:53 PM
	Revive Therapeutics Explores the Use of Bucillamine for Long COVID markets.businessinsider.com - February 1 at 9:20 AM
	Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500 markets.businessinsider.com - January 31 at 7:29 PM
	Revive Therapeutics Ltd. Announces Offering of Up to $3 Million financialpost.com - January 24 at 7:03 PM
	Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada tmcnet.com - January 16 at 8:29 AM
	Revive Therapeutics Ltd.: Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine finanznachrichten.de - January 10 at 2:05 PM
	Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine markets.businessinsider.com - January 10 at 9:05 AM
	Travere Therapeutics expects Q4 net product sales from continuing operations to be about $40M msn.com - January 8 at 4:03 PM
	Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders markets.businessinsider.com - December 20 at 5:50 PM
	Revive Therapeutics To Work With Attwill For Development Of Lyophilized Formulation Of Bucillamine markets.businessinsider.com - December 18 at 8:03 AM
	Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine financialpost.com - December 18 at 7:07 AM
	Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure markets.businessinsider.com - October 17 at 4:48 PM
	Revive Therapeutics Agrees With DRDC To Evaluate Bucillamine For Nerve Agent Exposure markets.businessinsider.com - October 17 at 11:47 AM
	Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development finanznachrichten.de - October 11 at 2:48 PM
	Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development tmcnet.com - October 11 at 9:47 AM
	Revive I-5 project continues with driving surface improvement work starting Monday komonews.com - October 11 at 12:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BriaCell Therapeutics

CVE:BCT

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Hemispherx BioPharma

NYSEAMERICAN:HEB

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

MOTIF BIO PLC/S

NASDAQ:MTFB

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Nanalysis Scientific

CVE:NSCI

Nanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies. It serves pharmaceutical, security, biotech, nutraceutical, chemical, food, materials, medical, and education industries. The company is headquartered in Calgary, Canada.

Revive Therapeutics

CVE:RVV

Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial